ARPA Bio

in tune with innovative solutions for early therapeutic intervention...

This WEBsite is still under construction. Please stay tuned for the lastest news and updates coming soon.

We are committed to targeting the root cause of neurodegenerative disorders through innovative approaches that enable early therapeutic intervention.

We are a Swiss, preclinical stage startup company, dedicated to developing innovative diagnostic tools and therapies for the treatment of neurodegenerative disorders. At ARPA Bio, we translate our scientific insights into highly selective and targeted treatments. Our latest research supports a novel, unparalleled approach for targeting early, pathological amyloid-beta (Aβ) species during the insidious phase of Alzheimer's disease, which clearly differentiates from earlier developed immuno-therapies.

ARPA Bio offers novel diagnostic and therapeutic solutions, which are uniquely designed to treat or even prevent the progression of Alzheimer's disease. Our patented technology targets key molecular events associated with the early-stage amyloid-beta oligomerization, facilitating timely interventions that could halt the progression of this debilitating condition. Our innovative tools ensure that potential oligomer formation is targeted before they lead to neurodegeneration and severe cognitive decline. ARPA Bio's proprietary targets enable early diagnosis and therapeutic intervention by targeting highly selective epitopes present in neurotoxic amyloid-beta species, which is why we clearly distinguish from the currently available clinical therapies for Alzheimer’s disease.